On January 10, 2023, Insilico Medicine, a clinical-stage artificial intelligence (AI)-driven drug R&D company, announced positive topline results of safety, tolerability, and pharmacokinetics (PK) from the Phase I clinical trial of INS018_055, a potential first-in-class drug discovered by Insilico's end-to-end AI platform for idiopathic pulmonary fibrosis (IPF). "Topline data from our Phase 1 study of INS018_055 demonstrate the ability of our Pharma.AI platform to discover novel targets and design novel molecules with a high level of translatability to human biology,” said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine. “This lead program is paving the way for a new era of drug discovery and development that utilizes next-generation AI to identify novel targets and generate novel drugs to treat diseases requiring regular peroral drug administration for the entire lifetime with very high safety requirements.”